Bio-Techne Introduces RNAscope Innovations for Biomarker Detection
Bio-Techne Corporation (NASDAQ: TECH) has made significant strides in its aim to enhance patient care through innovative biomarker detection technology. Their upcoming presentation focuses on RNAscope technologies, which are designed to meet the unmet needs in pathology laboratories. This initiative aligns with the company’s goal of translating groundbreaking discoveries into practical applications that can improve laboratory workflows.
Highlighting Key Advancements in Seminars
The company will present these advancements during the Annual Meeting of the United States and Canadian Academy of Pathology (USCAP). Renowned pathologists will partake in a seminar titled "RNAscope: Lightning Lunch and Learn," providing insights on the integration of RNAscope technology in clinical practice.
Notable Presentations from Leading Pathologists
During the seminar, the following pathologists will share their experiences:
- Dr. Rohit Mehra, from the University of Michigan, will discuss utilizing TRIM63 mRNA as a surrogate marker in translocation-associated renal cell carcinoma, demonstrating a compelling alternative to traditional DNA FISH methods.
- Dr. Vikram Deshpande, affiliated with Beth Israel Deaconess Medical Center, will explain how albumin mRNA is a superior marker compared to the currently used secreted proteins in primary and secondary liver tumors.
- Dr. Brooke Howitt, representing Stanford University, will showcase advancements in the in situ detection of point mutations within molecularly defined gynecologic tumors.
- Dr. Gregory Bean, also from Stanford University, will focus on the direct detection of mRNA linked to CRTC1/3::MAML2 translocations, providing alternatives to the traditional MAML2 FISH method for identifying mucoepidermoid carcinomas and hidradenomas.
Committed to Innovation in Pathology
Dr. Matt McManus, President of Bio-Techne's Diagnostics and Spatial Biology Segment, expressed excitement about these developments saying, "We have made incredible advancements in in situ hybridization methods that enable novel applications within pathology laboratories. This session at USCAP will illuminate the cutting-edge of clinical and translational research through the lens of our latest RNAscope technologies, aimed at understanding disease at the molecular level."
Bio-Techne remains dedicated to research use only, with a clear statement that its technologies are not intended for diagnostic procedures. With this focus, the company continues to pave the way for innovative methods in biomarker detection.
About Bio-Techne Corporation
Established as a leader in the life sciences sector, Bio-Techne Corporation (NASDAQ: TECH) offers an extensive range of innovative tools and bioactive reagents tailored for both research and clinical diagnostic communities. The company's diverse product portfolio supports scientific inquiries into biological mechanisms and enhances understanding of disease progression.
In the past fiscal year, Bio-Techne has reported around $1.2 billion in net sales, underlining its robust growth and commitment to scientific advancement. With a dedicated workforce of approximately 3,100 employees globally, Bio-Techne is poised to continue influencing the fields of drug discovery and clinical testing.
For additional information about Bio-Techne and its extensive range of products, visit the official website or follow their updates on various social media platforms.
Frequently Asked Questions
What is RNAscope technology?
RNAscope technology is an innovative method used to detect and visualize RNA in tissue samples, facilitating improved biomarker detection and pathology applications.
How does Bio-Techne contribute to pathology?
Bio-Techne enhances pathology laboratories by providing advanced reagents and technologies that streamline biomarker detection and improve workflow efficiency.
What are the main advantages of using RNAscope?
The main advantages of RNAscope include increased specificity for biomarkers, reduced time to results, and the ability to visualize RNA expression patterns directly within tissue samples.
Who are the pathologists presenting at the USCAP meeting?
The presenters include Dr. Rohit Mehra, Dr. Vikram Deshpande, Dr. Brooke Howitt, and Dr. Gregory Bean, each sharing their research findings using RNAscope technology.
What is Bio-Techne's financial performance?
In the latest fiscal year, Bio-Techne reported net sales of approximately $1.2 billion, highlighting its strong market position and commitment to innovation.
